To investigate miR-100-5p expression in GDM patients, assess its early predictive value for GDM development and association with glucose metabolism indicators/pregnancy outcomes, and clarify its regulatory role in trophoblast cell function. A total of 123 patients with GDM and 120 healthy pregnant women were enrolled. RT-qPCR detected serum miR-100-5p expression. ROC curve analyzed its diagnostic value. Pearson correlation analyzed the relationship between miR-100-5p and clinical indicators. Multivariate logistic regression identified risk factors for adverse pregnancy outcomes. In vitro, HTR8/SVneo cells were treated with high glucose, and miR-100-5p inhibitor was transfected to detect cell function via CCK-8 and Transwell assays. Serum miR-100-5p in GDM group was significantly higher than control, with AUC = 0.914 for GDM diagnosis. miR-100-5p was positively correlated with HbA1c, HOMA-IR, LEP, and FBG. High miR-100-5p expression was an independent risk factor for adverse outcomes. High glucose upregulated miR-100-5p in trophoblast cells, and inhibitor reversed high glucose-induced inhibition of cell proliferation, migration and invasion. miR-100-5p is highly expressed in GDM, showing promising diagnostic potential. Preliminary evidence suggests it is associated with glucose metabolism and adverse outcomes, and may serve as a potential therapeutic target, providing a basis for further investigation into GDM intervention.
Sun et al. (Tue,) studied this question.